Mitochondrial niches of residual disease in EGFR-mutant NSCLC: immune-constrained persistence and therapeutic interception
Zhanhao Liang, Xutong Zhao, Mingru Jiang, Meizhu Zhou, Miao Cheng, Shibiao Liu, Yi Zhao · 2026
Read Mitochondrial niches of residual disease in EGFR-mutant NSCLC: immune-constrained persistence and therapeutic interception by Zhanhao Liang, Xutong Zhao, Mingru Jiang, Meizhu Zhou, Miao Cheng, Shibiao Liu, Yi Zhao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13548500.txt.
Description
Zhanhao Liang and co-authors propose a new frame for stubborn lung cancer in a 2026 review. In EGFR-mutant lung cancer, targeted drugs often shrink the tumor yet leave a few cells alive. Those leftover cells are usually lumped with later drug resistance. The authors argue they form an earlier, distinct phase worth attacking on its own.
Their mitochondrial niche model links stressed cell powerhouses, support tissue, and weak immune clearing on one timeline. They stress the niche is a hypothesis, not yet shown to act as one unit. Marker candidates include blood DNA traces and tissue signs. Readers get testable questions for trials that strike before resistance sets in.
Catalog record
| CREATOR | Zhanhao Liang, Xutong Zhao, Mingru Jiang, Meizhu Zhou, Miao Cheng, Shibiao Liu, Yi Zhao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 96 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |